Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 100/164 ]
NASDAQ | Common Stock
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally.
The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product.
In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 8, 24 | -0.08 Increased by +87.10% | -0.21 Increased by +61.90% |
| Nov 13, 23 | -0.29 Increased by +12.12% | -0.24 Decreased by -20.83% |
| Aug 10, 23 | -0.28 Increased by +70.57% | -0.12 Decreased by -133.00% |
| Jun 21, 23 | -0.31 Increased by 0.00% | - |
| Feb 14, 23 | -0.62 Decreased by -1.45 K% | - |
| Nov 14, 22 | -0.33 Increased by +81.25% | - |
| Jul 13, 22 | -0.95 Decreased by -81.09% | - |
| Feb 11, 22 | -0.31 Increased by +3.13% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 3.14 M Increased by +6.59% | -866.00 K Increased by +55.34% | Decreased by -27.60% Increased by +58.10% |
| Sep 30, 23 | 2.73 M Decreased by -18.01% | -1.48 M Decreased by -45.92% | Decreased by -54.34% Decreased by -77.98% |
| Jun 30, 23 | 3.43 M Increased by +49.13% | -1.42 M Increased by +51.83% | Decreased by -41.38% Increased by +67.70% |
| Mar 31, 23 | 3.01 M Increased by +31.16% | -1.31 M Increased by +55.57% | Decreased by -43.40% Increased by +66.13% |
| Dec 31, 22 | 2.94 M Increased by +1.45% | -1.94 M Decreased by -105.40% | Decreased by -65.86% Decreased by -102.47% |
| Sep 30, 22 | 3.33 M Decreased by -11.03% | -1.02 M Decreased by -917.00% | Decreased by -30.53% Decreased by -1.04 K% |
| Jun 30, 22 | 2.30 M Increased by +6.54% | -2.94 M Increased by +19.56% | Decreased by -128.11% Increased by +24.50% |
| Mar 31, 22 | 2.30 M Increased by +6.54% | -2.94 M Increased by +19.56% | Decreased by -128.11% Increased by +24.50% |